Orforglipron (Foundayo), approved by the FDA: the first GLP-1 pill that can be taken without food or water restrictions

For years, the big drawback of GLP-1s was the needle. Orforglipron arrives with a different promise: a daily tablet that, according to its manufacturer, can be taken at any time of day with no food or water restrictions. The FDA approved it under the brand name Foundayo on 1 April 2026 for adults with obesity, or with overweight and weight-related medical problems, always alongside a reduced-calorie diet and increased physical activity. It is worth saying this before quoting any figures: orforglipron is not authorised in Spain. There is no confirmation of EMA authorisation, no summary of product characteristics in CIMA-AEMPS, no marketing and no funding by the Spanish National Health System. The only documented fact is that Lilly states it has submitted the drug in more than 40 countries for weight management and/or type 2 diabetes. That said, there is quite a lot that is known, and it is worth understanding properly.

What orforglipron is and why it is not the same as semaglutide in tablet form

The most widespread confusion is calling it "Ozempic in a pill". It is not. Semaglutide and liraglutide are peptides: chains of amino acids, large and fragile molecules that the digestive system tends to destroy. That is why they are injected, and why oral semaglutide needs an absorption enhancer and fairly strict conditions for taking it.

Orforglipron is something else: a small-molecule, non-peptide GLP-1 receptor agonist. It acts on the same target, the GLP-1 receptor, but from a completely different chemistry. That is the technical reason it can be formulated as a conventional tablet. If you want to understand exactly what this family of drugs does in the body, we have a detailed explanation in our guide on what GLP-1s are and how they work in obesity.

Phase 3 tested doses of 6, 12 and 36 mg daily, taken once a day. The claim that it is "the only GLP-1 tablet for weight loss that can be taken at any time of day with no food or water restrictions" comes from the manufacturer's own press release, and should be attributed as such. Independent coverage in Pharmacy Times reported the approval with a headline along the same lines, but we have not verified that this "only" or "first" status is endorsed by the FDA as such.

What ATTAIN-1, the obesity trial, found

ATTAIN-1 was a phase 3, randomised, double-blind, placebo-controlled, multinational trial lasting 72 weeks, published in the New England Journal of Medicine on 16 September 2025 and presented at the EASD congress in Vienna. It included 3,127 adults with obesity, or with overweight and one weight-related complication, without diabetes. Three doses were compared, 6, 12 and 36 mg daily, against placebo.

Average weight loss results at 72 weeks rose with the dose: 7.8% with 6 mg, 9.3% with 12 mg and 12.4% with 36 mg, compared with 0.9% on placebo. That 12.4% is equivalent to about 27.3 pounds on average.

There is one nuance that almost never makes the headlines and that changes how you read the figure. The 12.4% corresponds to the so-called efficacy estimand, that is, the effect estimated if the treatment is taken as intended. There is another way of analysing the same data, the treatment-regimen estimand, which factors in what happens when people drop out or interrupt treatment; with it, the 36 mg dose comes to 11.2%, compared with 2.1% on placebo, according to the NEJM paper. In plain terms: 12.4% is not what each person is going to lose. It is an average, on the highest dose, at 72 weeks and under the most favourable assumption about adherence.

As for the secondary endpoints, ATTAIN-1 met those for the proportion of patients losing at least 10%, 15% and 20% of their weight, and for the reduction in waist circumference, across all three doses versus placebo. The specific verified figure: 59.6% of those on the highest dose achieved a loss of at least 10%.

It is a pill, but it is still a GLP-1

Taking it by mouth does not make it a harmless drug. In ATTAIN-1, adverse effects were mainly gastrointestinal, mild to moderate, and consistent with what is already known about the GLP-1 class: the typical profile of nausea and digestive discomfort that appears above all at the start and during dose increases. If you are interested in the detail of how these present and how they are managed clinically with the drugs already available, we cover it in our article on the side effects of Ozempic and Mounjaro and how to manage them.

On specific warnings for Foundayo, contraindications or the exact approved dosing schedule, we do not have verified information from the US label and therefore we are not writing it. That is information that belongs in the official patient information leaflet and in the assessment made by a doctor, not in a general health article.

Another important nuance: "no food restriction" refers to taking the tablet, not to the diet. The indication approved by the FDA is explicit that the drug is used as an adjunct to a reduced-calorie diet and increased physical activity. It is not permission to eat whatever you like.

What is known in type 2 diabetes (and what is not approved)

The verified approval of Foundayo is only for obesity and overweight with a comorbidity. It is not approved for type 2 diabetes. In April 2025 Lilly indicated that the regulatory submission for that indication was expected in 2026, but that is an expectation, not an authorisation.

Even so, there is published evidence. ACHIEVE-1 was a 40-week phase 3 trial in 559 adults with type 2 diabetes managed with diet and exercise alone, with HbA1c between 7.0 and 9.5% and a BMI of 23 or above, randomised 1:1:1:1 to 3, 12 or 36 mg or placebo, with change in HbA1c at week 40 as the primary endpoint. At baseline, participants had had diabetes for an average of 4.4 years, with a mean HbA1c of 8.0% (64 mmol/mol), a weight of 90.2 kg and a BMI of 33.0 kg/m².

According to the trial paper published in the NEJM, the reduction in HbA1c at 40 weeks was −1.24 points with 3 mg, −1.47 with 12 mg and −1.48 with 36 mg, compared with −0.41 on placebo. Weight change over the same period was −4.5%, −5.8% and −7.6% respectively, versus −1.7% on placebo. If your starting point is impaired blood glucose rather than established diabetes, you may find our guide to prediabetes and how it is managed useful.

Why you cannot compare it with Wegovy or Mounjaro

It is the immediate temptation: take orforglipron's 12.4% and set it alongside the percentage you remember for another drug. It does not work like that. ATTAIN-1 was compared against placebo, not against semaglutide or tirzepatide. There is no verified head-to-head comparison between orforglipron and either of them.

Comparing percentages across different trials is methodologically wrong, and not out of purism: the populations, the duration, the inclusion criteria, the design of the accompanying diet and the way dropouts are analysed all vary from one study to another and shift the results by several points. To see just how much design nuances matter, a good illustration is the case of the clinical differences between Mounjaro and Ozempic, where a head-to-head comparison does exist.

Nor is there any verified data on what happens when orforglipron is stopped. It is a relevant question, because with other drugs in the family weight tends to come back once treatment is interrupted; we explain this in our article on why weight comes back after stopping treatment. Applying to orforglipron what has been observed with other molecules would be a reasonable assumption, but it would still be an assumption.

The situation in Spain

To repeat what we said at the outset: there is no confirmation of EMA authorisation, no summary of product characteristics published in CIMA-AEMPS, and no marketing or public funding in Spain. What is verifiable is the manufacturer's statement that it has submitted orforglipron in more than 40 countries for weight management and/or type 2 diabetes, and that in the United States it is distributed through LillyDirect with shipments from 6 April 2026, and subsequently in retail pharmacies and telehealth.

When a drug generates expectation before it is available, a parallel market appears: websites promising to ship it from abroad, "generic" versions that do not exist, vials of unknown origin. The AEMPS has issued information notices about falsified medicines and the illegal sale of GLP-1 analogues. Buying a prescription medicine outside the legal channel is not a shortcut, it is a real risk with no guarantees. On how the legal route works in Spain for the drugs that are available, we set it out in our guide to how to obtain Ozempic and Mounjaro legally and safely.

In summary

Orforglipron is significant news because it opens the door to a GLP-1 in tablet form with convenient conditions for taking it, but today it is a drug approved in the United States, with no availability or confirmed authorisation in Spain, and with data that cannot be compared directly with that of the injectables. What does exist here and now is something else: medical weight-loss treatment with a prior assessment, a prescription where appropriate from a registered doctor and ongoing follow-up, without depending on what gets approved on the other side of the Atlantic. At AiON you can check whether you are eligible in a few minutes and take the first step with real support.